Press Releases and Events

PRESS RELEASES

Press Release | September 10, 2025

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | August 21, 2025

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

READ MORE
Press Release | August 11, 2025

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | August 7, 2025

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

READ MORE
Press Release | July 13, 2025

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

READ MORE
Press Release | July 11, 2025

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

READ MORE
Press Release | July 10, 2025

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | June 30, 2025

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

READ MORE
Press Release | June 16, 2025

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

READ MORE
Press Release | June 10, 2025

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
4 / 25